Compugen Ltd. (CGEN) Key Metrics
CGEN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $185.7M
- Enterprise value
- $110.3M
- P/E (TTM)
- 5.2
- Forward P/E
- 12.4
- PEG ratio
- 1.29
- Price / sales
- 2.5 10-yr median 7.5
- Price / book
- 2.5 10-yr median 3.3
- EV / EBITDA
- 3.6
- Dividend yield
- —
- Beta
- 2.79
CGEN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCGEN valuation Price multiples at each fiscal year-end price.
CGEN returns How much profit the business earns on the capital it uses.
CGEN per-share figures Results divided by the shares outstanding at year-end.
CGEN financial health Debt, liquidity and how easily interest is covered.
CGEN efficiency & capital use Working capital cycle and where the cash goes.
CGEN valuation history
CGEN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CGEN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CGEN price vs earnings per share
CGEN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $143.5M | $137.0M | $173.5M | $61.9M | $362.1M | $963.8M | $379.3M | $120.0M | $127.9M | $259.4M |
| Enterprise value | $857,077 | $36.6M | $124.2M | −$19.5M | $247.8M | $843.3M | $339.0M | $77.3M | $97.8M | $197.8M |
| P/E ratio | 4.1 | — | — | — | — | — | — | — | — | — |
| Price / sales | 2.0 | 4.9 | 5.2 | 8.3 | 60.3 | 481.9 | — | 6.7 | — | 364.3 |
| Price / book | 1.4 | 2.5 | 2.6 | 0.8 | 3.4 | 8.0 | 9.9 | 3.2 | 4.4 | 4.1 |
| Price / free cash flow | 4.6 | 2.8 | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 4.5 | 2.8 | — | — | — | — | — | — | — | — |
| EV / sales | 0.0 | 1.3 | 3.7 | -2.6 | 41.3 | 421.6 | — | 4.3 | — | 277.9 |
| EV / EBITDA | 0.0 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | 0.0 | 0.7 | — | — | — | — | — | — | — | — |
| Earnings yield | 24.6% | −10.4% | −10.8% | −54.4% | −9.1% | −2.8% | −7.2% | −18.8% | −29.0% | −12.1% |
| Free cash flow yield | 21.8% | 36.1% | −20.8% | −55.9% | −6.3% | −3.0% | −7.4% | −11.2% | −24.3% | −8.6% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $1.53 | $1.53 | $1.98 | $0.72 | $4.30 | $12.11 | $5.96 | $2.17 | $2.50 | $5.10 |
| Per share | ||||||||||
| Revenue per share | $0.78 | $0.31 | $0.38 | $0.09 | $0.07 | $0.03 | $0.00 | $0.32 | $0.00 | $0.01 |
| Earnings per share | $0.38 | −$0.16 | −$0.21 | −$0.39 | −$0.39 | −$0.34 | −$0.43 | −$0.41 | −$0.72 | −$0.62 |
| Operating cash flow per share | $0.34 | $0.55 | −$0.41 | −$0.39 | −$0.27 | −$0.36 | −$0.44 | −$0.24 | −$0.60 | −$0.39 |
| Free cash flow per share | $0.33 | $0.55 | −$0.41 | −$0.40 | −$0.27 | −$0.36 | −$0.44 | −$0.24 | −$0.61 | −$0.44 |
| Cash per share | $1.55 | $1.15 | $0.58 | $0.96 | $1.39 | $1.56 | $0.69 | $0.83 | $0.59 | $1.21 |
| Book value per share | $1.10 | $0.61 | $0.75 | $0.90 | $1.27 | $1.50 | $0.60 | $0.67 | $0.57 | $1.25 |
| Tangible book value per share | $1.10 | $0.61 | $0.75 | $0.90 | $1.27 | $1.50 | $0.60 | $0.67 | $0.57 | $1.25 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 | $0.05 |
| Debt per share | $0.03 | $0.03 | $0.02 | $0.02 | $0.03 | $0.04 | $0.06 | $0.05 | $0.01 | — |
| Shares outstanding | 93.8M | 89.5M | 87.6M | 86.6M | 84.2M | 79.6M | 63.6M | 55.3M | 51.2M | 50.9M |
| Change in shares outstanding | +4.8% | +2.2% | +1.2% | +2.8% | +5.8% | +25.1% | +15.1% | +8.0% | +0.6% | +0.8% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 44.8% | −23.6% | −26.2% | −36.5% | −29.0% | −34.5% | −72.4% | −67.9% | −79.9% | −41.1% |
| Return on invested capital (ROIC) | — | — | −164.4% | — | — | — | — | — | — | −512.7% |
| Return on assets (ROA) | 26.0% | −12.0% | −17.4% | −29.8% | −24.3% | −28.4% | −51.1% | −49.2% | −67.5% | −37.0% |
| Return on tangible assets | 22.5% | −12.4% | −15.5% | −35.8% | −24.9% | −19.7% | −50.8% | −42.5% | −95.7% | −44.3% |
| Free cash flow margin | 43.1% | 177.6% | −107.8% | −461.3% | −383.1% | — | — | −75.6% | — | — |
| Income quality (OCF / net income) | 0.90 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $3.0M | $2.9M | $1.4M | $1.9M | $2.8M | $3.2M | $3.6M | $3.0M | $312,000 | — |
| Cash & short-term investments | $145.6M | $103.3M | $50.7M | $83.3M | $117.0M | $123.8M | $43.9M | $45.7M | $30.4M | $61.5M |
| Net debt | −$142.7M | −$100.3M | −$49.3M | −$81.4M | −$114.3M | −$120.6M | −$40.3M | −$42.7M | −$30.1M | −$61.5M |
| Debt / equity | 0.03 | 0.05 | 0.02 | 0.02 | 0.03 | 0.03 | 0.09 | 0.08 | 0.01 | — |
| Debt / assets | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 | 0.02 | 0.07 | 0.06 | 0.01 | — |
| Net debt / EBITDA | −3.98 | — | — | — | — | — | — | — | — | — |
| Current ratio | 6.56 | 5.26 | 4.36 | 7.23 | 7.21 | 12.27 | 6.60 | 4.66 | 5.03 | 13.22 |
| Quick ratio | 6.56 | 5.26 | 4.36 | 13.32 | 7.56 | 23.60 | 6.71 | 4.80 | 5.31 | 13.66 |
| Interest coverage | — | -438.0 | -419.1 | — | -40.4 | -18.3 | -16.0 | -37.5 | -73.6 | -46.2 |
| Working capital | $125.5M | $85.8M | $88.3M | $74.2M | $106.1M | $118.6M | $38.2M | $36.6M | $25.0M | $57.9M |
| Invested capital | −$39.9M | −$45.4M | $16.2M | −$3.7M | −$7.6M | −$817,000 | −$2.0M | −$5.4M | −$829,000 | $2.0M |
| Tangible asset value | $102.7M | $54.9M | $65.6M | $77.7M | $106.7M | $119.8M | $38.3M | $37.2M | $29.3M | $63.5M |
| Net current asset value | $93.9M | $45.9M | $58.8M | $69.6M | $97.8M | $110.6M | $29.6M | $30.6M | $21.7M | $55.1M |
| Graham number | $3.05 | — | — | — | — | — | — | — | — | — |
| Graham net-net per share | $0.98 | $0.48 | $0.47 | $0.36 | $1.05 | $0.59 | $0.44 | $0.53 | $0.40 | $1.04 |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.4% | 0.4% | 0.5% | 6.5% | 4.9% | 8.3% | — | 0.9% | — | 365.0% |
| Capex / operating cash flow | 1.0% | 0.2% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.64 | 0.24 | 0.36 | 1.01 | 0.63 | 0.23 | 0.16 | 0.11 | 0.24 | 1.75 |
| Stock-based compensation / revenue | 2.6% | 10.8% | 10.6% | 57.7% | 71.3% | 138.6% | — | 12.2% | — | 433.1% |
| R&D / revenue | 31.3% | 89.0% | 103.0% | 408.6% | 478.2% | 1,138.0% | — | 170.3% | — | 3,447.9% |
| SG&A / revenue | 13.0% | 35.9% | 29.8% | 150.0% | 195.0% | 533.8% | — | 54.4% | — | 1,197.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 1.4 | 403.4 | 336.2 | 12.3 | 66.6 | 213.6 | — | 9.3 | — | 2,180.5 |
| Days of inventory on hand | — | — | — | -14,718.7 | -33,621.3 | -365,209.9 | -391.4 | -543.8 | -435.8 | -3,165.5 |
| Days payables outstanding | 82.7 | 122.9 | 480.4 | 1,196.8 | 1,619.4 | 7,607.2 | 744.4 | 1,128.0 | 540.6 | 2,680.2 |
| Cash conversion cycle (days) | -81.3 | 280.5 | -144.2 | -15,903.2 | -35,174.2 | -372,603.5 | — | -1,662.5 | — | -3,665.2 |
| Receivables turnover | 258.49 | 0.90 | 1.09 | 29.70 | 5.48 | 1.71 | 0.00 | 39.21 | 0.00 | 0.17 |
| Payables turnover | 4.41 | 2.97 | 0.76 | 0.30 | 0.23 | 0.05 | 0.49 | 0.32 | 0.68 | 0.14 |
| Asset turnover | 0.54 | 0.24 | 0.31 | 0.07 | 0.04 | 0.02 | 0.00 | 0.39 | 0.00 | 0.01 |
| Average receivables | $281,500 | $30.8M | $30.8M | $252,500 | $1.1M | $1.2M | $254,000 | $454,000 | $411,500 | $4.3M |
| Average payables | $2.1M | $2.7M | $2.6M | $3.2M | $3.0M | $1.3M | $2.0M | $3.2M | $2.4M | $1.6M |
| Average inventory | — | — | — | −$39.3M | −$62.6M | −$60.0M | −$1.1M | −$1.5M | −$1.9M | −$1.9M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CGEN's annual financial statements (latest annual report filed March 2, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CGEN valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Compugen traded at 4.1 times earnings. Based on the latest twelve months, the trailing P/E is 5.2 and the forward P/E is 12.4. Compugen earned a return on equity of 44.8% in fiscal 2025. It ended the year with $3.0 million of debt and $145.6 million in cash and short-term investments, a net cash position of $142.7 million. The share count rose 84.5% from 50.9M to 93.8M over 9 years.
See the CGEN income statement, the CGEN chart for price history, or the CGEN stock overview for the latest quote and news.
CGEN key metrics FAQ
What is Compugen's P/E ratio?
Compugen's trailing P/E ratio is 5.2 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 12.4. At the end of fiscal 2025 it was 4.1.
What is Compugen's EV/EBITDA?
Compugen's enterprise value was 0.0 times EBITDA at the end of fiscal 2025 (enterprise value $0.9 million, EBITDA $35.9 million); the current EV/EBITDA is 3.6.
What is Compugen's return on equity?
Compugen's return on equity (ROE) was 44.8% in fiscal 2025: net income of $35.3 million on average shareholders' equity of $78.8 million.
How much debt does Compugen have?
Compugen had total debt of $3.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Compugen's free cash flow yield?
Compugen generated $31.3 million of free cash flow in fiscal 2025, a free cash flow yield of 21.8% on its market value at year-end ($143.5 million).
What is Compugen's current ratio?
Compugen's current ratio was 6.56 at the end of fiscal 2025: current assets were 6.56 times current liabilities.